

Osteosarcoma Therapeutic and Overview Pipeline Review H2

Osteosarcoma Treatment Pipeline Review H2 2016

PUNE, INDIA, November 11, 2016

/EINPresswire.com/ -- The report provides comprehensive information on the therapeutics under development for [Osteosarcoma](#), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteosarcoma and features dormant and discontinued projects.



WISE GUY
REPORTS

Norah Trent Partner Relations & Marketing Manager

✉ sales@wiseguyreports.com

☎ Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK)

🌐 <https://www.linkedin.com/company/4828928>

🐦 <https://twitter.com/WiseGuyReports>

📘 <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Wise.Guy.

Get Sample Report @ <https://www.wiseguyreports.com/sample-request/643470-osteosarcoma-pipeline-review-h2-2016>

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Osteosarcoma
- The report reviews pipeline therapeutics for Osteosarcoma by companies and

universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Osteosarcoma therapeutics and enlists all their major and minor projects
- The report assesses Osteosarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Osteosarcoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Osteosarcoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Osteosarcoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 8

List of Figures 9

Introduction 10

Osteosarcoma Overview 11

Therapeutics Development 12

Pipeline Products for Osteosarcoma - Overview 12

Pipeline Products for Osteosarcoma - Comparative Analysis 13

Osteosarcoma - Therapeutics under Development by Companies 14

Osteosarcoma - Therapeutics under Investigation by Universities/Institutes 16

Osteosarcoma - Pipeline Products Glance 17
Clinical Stage Products 17
Early Stage Products 18
Osteosarcoma - Products under Development by Companies 19
Osteosarcoma - Products under Investigation by Universities/Institutes 20
Osteosarcoma - Companies Involved in Therapeutics Development 21
Advaxis, Inc. 21
Amgen Inc. 22
AVEO Pharmaceuticals, Inc. 23
Bayer AG 24
Bellicum Pharmaceuticals, Inc. 25
Celldex Therapeutics, Inc. 26
CytRx Corporation 27
Eleison Pharmaceuticals LLC 28
Exelixis, Inc. 29
Isofol Medical AB 30
MediaPharma s.r.l. 31
Merck & Co., Inc. 32
Merrimack Pharmaceuticals, Inc. 33
Netris Pharma S.A.S. 34
Novartis AG 35
Oncolys BioPharma Inc 36
Pfizer Inc. 37
Shionogi & Co., Ltd. 38
Teijin Pharma Limited 39
United Therapeutics Corporation 40
Osteosarcoma - Therapeutics Assessment 41
Assessment by Monotherapy Products 41
Assessment by Target 42
Assessment by Mechanism of Action 45
Assessment by Route of Administration 48
Assessment by Molecule Type 50
Drug Profiles 52
3D-QM - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
3D-QMS - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
ADX-HER2 - Drug Profile 54
Product Description 54

Mechanism Of Action 54

R&D Progress 54

aldoxorubicin hydrochloride - Drug Profile 58

Product Description 58

Access Report @ <https://www.wiseguyreports.com/reports/643470-osteosarcoma-pipeline-review-h2-2016> □

Get in touch:

LinkedIn: www.linkedin.com/company/4828928

Twitter: <https://twitter.com/WiseGuyReports>

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/353451668>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2020 IPD Group, Inc. All Right Reserved.